<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00652704</url>
  </required_header>
  <id_info>
    <org_study_id>99062</org_study_id>
    <nct_id>NCT00652704</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions</brief_title>
  <official_title>Randomized, Open-Label, 3-Way Crossover, Comparative Bioavailability Study of Par's and Oclassen's (Monodox) Doxycycline Monohydrate Capsules Administered as 1 x 100 mg Capsule in Healthy Adult Males Under Fasting and Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anapharm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the rate and extent of absorption of doxycycline monohydrate capsules equivalent
      to 100 mg doxycycline (Par) versus Monodox (Oclassen Pharmaceuticals)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the rate and extent of absorption of doxycycline monohydrate capsules equivalent
      to 100 mg doxycycline by Par Pharmaceutical Inc., USA (test) versus Monodox by Oclassen
      Pharmaceuticals, Inc., USA (reference) administered as a 1 x 100 mg capsule under fasting and
      fed conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">September 1999</completion_date>
  <primary_completion_date type="Actual">September 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and extent of absorption</measure>
    <time_frame>72 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>To Determine Bioequivalence Under Fed Conditions</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received the reference product, Monodox (Oclassen) under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline monohydrate</intervention_name>
    <description>Capsules, 100 mg, fed</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Monodox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monodox</intervention_name>
    <description>Capsules, 100 mg, fed</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Doxycycline Monohydrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline Monohydrate</intervention_name>
    <description>Capsules, 100 mg, fasting</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Monodox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be males, non-smokers

          -  Between 18 and 55 years of age

          -  Subjects weight will be within 15% of their ideal body weight, based on Table of
             &quot;Desirable Weight of Adults&quot;, Metropolitan Life Insurance Company, 1983

          -  Subjects should read, sign and date an Informed Consent Form prior to any study
             procedures

          -  Subjects must complete all screening procedures within 28 days prior to the
             administration of the study medication

        Exclusion Criteria:

          -  Clinically significant anormalities found during medical screening

          -  Any clinically significant history of ongoing problems or problems known to interfere
             with the absorption, distribution, metabolism or excretion of drugs of drugs

          -  Clinically significant illnesses within 4 weeks of the administration of study
             medication

          -  Abnormal laboratory tests judged clinically significant

          -  ECG or vital sign abnormalities (clinically significant)

          -  History of allergic reactions to heparin

          -  Any food allergies, intolerances, restrictions, or special diet which in the opinion
             of the medical subinvestigator, contraindicates the subject's participation in the
             study

          -  History of severe allergies or hay fever

          -  Active asthma or bronchospasm

          -  Positive urine drug screen at screening

          -  Positive testing for hepatitis B, hepatitis C or HIV at screening

          -  Use of investigational drug or participation in an investigational study, within 30
             days prior to administration of the study medication

          -  Recent donation of plasma (500 mL) within 7 days or recent donation or significant
             loss of whole blood (450 mL) within 56 days prior to the administration of the study
             medication

          -  History of significant alcohol abuse within six months of the screening visit or any
             indication of the regular use of more than two units of alcohol per day

          -  Recent history of drug abuse or use of illegal drugs: soft drugs (marijuana, pot) use
             within 3 months of the screening visit and hard drugs (cocaine, PCP, crack) use within
             1 year of the screening visit

          -  Subjects who have taken prescription medication 14 days preceding administration of
             study medication or over-the-counter products 7 days preceding administration of study
             medication, except for topical products without systemic absorption

          -  Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism
             within 30 days prior to administration of the study medication

          -  Subjects who have undergone clinically significant surgery within 4 weeks prior to the
             administration of the study medication

          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the
             subject from participating in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Masson, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm, Inc.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2008</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <name_title>Alfred Elvin/Director of Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc.</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Doxycycline Monohydrate</keyword>
  <keyword>Fed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

